This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline
by Zacks Equity Research
Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from strong segmental performance.
Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts
by Zacks Equity Research
Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
AngioDynamics' (ANGO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AngioDynamics (ANGO).
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.
AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.
AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.
Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.
Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.
Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.
LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.